ImmuneOnco Biopharmaceuticals (Shanghai) Inc. Announces Major Wealth Management Transactions: Redemption and New Subscription Totaling Over HK\$417 Million
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (Stock Code: 1541), a clinical-stage biotechnology company specializing in immuno-oncology therapies, has issued a significant update regarding its treasury management activities, which may be of keen interest to shareholders and the investment community.
Key Highlights
- Full Redemption of previous wealth management product (the “Shenwan Product”) totaling HK\$205,000,000 with an estimated unaudited gain of HK\$4,969,000.
- New Subscription on the same day for a structured note wealth management product (the “Shenwan Subscription Product”) totaling HK\$212,000,000 with an expected annualized return of 2.0% to 4.5%.
- Both transactions are classified as discloseable transactions under Chapter 14 of the Hong Kong Listing Rules, but do not require shareholder approval.
Details of the Transactions
Redemption of Wealth Management Product
ImmuneOnco subscribed for the first Shenwan Product on June 16, 2025, using internal surplus cash reserves. On May 22, 2026, the company redeemed the full HK\$205 million principal, realizing an estimated unaudited interest income of HK\$4,969,000. The proceeds will be used for general working capital and potential short-term cash management investments.
This move aligns with the company’s treasury policy to optimize idle funds and improve returns. After this redemption, ImmuneOnco no longer holds any outstanding wealth management products from Shenwan Hongyuan Securities (H.K.).
New Subscription of Wealth Management Product
On the same day as the redemption, ImmuneOnco subscribed to a new structured note wealth management product from Shenwan Hongyuan Securities (H.K.), with a principal of HK\$212,000,000. The product is a one-year, redeemable structured note linked to cash management funds, with expected returns ranging from 2.0% to 4.5% based on the performance of underlying assets such as cash, bank deposits, certificates, and short-term U.S. Treasury bonds.
The subscription was again funded by the company’s surplus cash reserves, ensuring this investment does not impact the company’s working capital or operations. The terms were negotiated at arm’s length and are viewed by the Board as fair and beneficial to shareholders.
Strategic Rationale
- Maximizing Returns: The company aims to make full use of idle funds to enhance income without compromising liquidity or risk profile.
- Risk Management: The new investment maintains a low risk profile and offers flexibility with the ability to redeem on ten business days’ notice.
- Shareholder Interests: The Board believes these transactions are in the best interests of the company and shareholders, supporting both capital preservation and incremental returns.
Potential Impact for Shareholders
- The recognized gain from the redemption (HK\$4.97 million) will positively affect short-term earnings, subject to audit confirmation.
- The move to a new, higher principal investment (HK\$212 million vs. HK\$205 million) signals confidence in the company’s cash flow and financial stability.
- The expected returns (up to 4.5% p.a.) may provide enhanced yield compared to idle cash, supporting shareholder value.
- No dilution or additional risk to shareholders as the transactions are funded from existing cash reserves and do not affect operations.
Company and Counterparty Information
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.: Clinical-stage biotech focused on immuno-oncology, incorporated in the PRC, listed on HKEX since June 2022.
- Shenwan Hongyuan Securities (H.K.): Subsidiary of Shenwan Hongyuan (H.K.) Limited, part of Shenwan Hongyuan Group Co., Ltd., a major PRC-listed brokerage and financial group.
- Counterparties are confirmed as independent third parties under HK Listing Rules.
Listing Rules Implications
Both the redemption and the new subscription are considered discloseable transactions under Chapter 14 of the Listing Rules, with relevant disclosure and notification obligations. However, shareholder approval is not required given the scale (applicable percentage ratios exceed 5% but are below 25%).
Board Statement
The Board, comprising executive, non-executive, and independent non-executive directors, unanimously supports these transactions as prudent and consistent with the company’s treasury and risk management policies.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult professional advisors before making any investment decisions. Past performance is not indicative of future results. All information is based on company disclosures as of May 22, 2026, and is subject to change without notice.
免疫安科生物醫藥（上海）股份有限公司公布重大財務動向：贖回及新認購超過4.17億港元理財產品
免疫安科生物醫藥（上海）股份有限公司（股份代號：1541），一家專注於腫瘤免疫治療的臨床階段生物科技公司，最新披露其財資管理動向，對股東及投資者具潛在重大影響。
重點摘要
- 全額贖回 先前申購的理財產品（「申萬產品」），金額達2.05億港元，預計未經審核收益496.9萬港元。
- 同日新認購 另一結構性票據理財產品（「申萬新產品」），金額為2.12億港元，預期年化回報2.0%至4.5%。
- 兩項交易均屬於《上市規則》第14章下的須予披露交易，但無需股東批准。
交易詳情
理財產品贖回
公司於2025年6月16日以內部結餘資金申購「申萬產品」。2026年5月22日，免疫安科全額贖回該產品，實現預計未經審核利息收益496.9萬港元。贖回所得將用於營運資金及短期現金管理投資。
此舉符合公司財資政策，旨在優化閒置資金回報。贖回後，公司將不再持有任何申萬產品。
新理財產品認購
贖回同日，公司以2.12億港元申購新結構性票據理財產品，為期一年，可提前10個工作日通知贖回。預期年化回報為2.0%至4.5%，投資標的包括現金、銀行存款、存單、短期美國國債等。
資金來源為公司內部結餘，不影響營運資金和日常運作。董事會認為條款公平合理，有利股東整體利益。
策略及潛在影響
- 提升回報： 充分利用閒置資金，兼顧收益和流動性。
- 風險可控： 低風險、靈活贖回，確保資金安全。
- 股東權益： 有助於資本保值增值，無稀釋及額外風險。
對股東的影響
- 贖回收益（496.9萬港元）將正面影響短期盈利，具提振因素，實際收益仍待審核確認。
- 新認購金額增加（2.12億對2.05億），顯示公司現金流穩健。
- 預期回報提高（高至4.5%），有望提升資金收益，利好公司整體價值。
- 資金來源為自有現金，不影響日常經營。
公司及對手方資料
- 免疫安科生物醫藥： 臨床階段腫瘤免疫治療公司，2022年上市。
- 申萬宏源證券（香港）： 申萬宏源（香港）有限公司全資子公司，母公司為申萬宏源集團，中港兩地上市大型券商。
- 交易對方均為獨立第三方。
上市規則影響
本次贖回及新認購均屬於須予披露交易，依法公開披露，毋須股東大會批准。
董事會聲明
董事會（包括執行、非執行及獨立非執行董事）一致認為本次交易審慎合理，符合公司財資及風險管理政策，有利公司及股東整體利益。
免責聲明： 本文僅供參考，不構成投資建議。投資者應自行進行調查，並咨詢專業顧問。過往表現不代表未來結果。所有資料截至2026年5月22日，以公司公告為準，隨時可能變更。
